Stockpile boost for Biota
Monday, 02 February, 2009
The UK Government has purchased over 10 million treatment courses of zanamivir, the flu antiviral developed by Biota and marketed by GlaxoSmithKline as Relenza.
The Government also bought an extra eight million courses of oseltamivir, the antiviral marketed as Tamiflu by Roche. Evidence is emerging of resistance to Tamiflu, the market-leading flu treatment.
The purchase means the UK now has enough antivirals stockpiled to treat 50 per cent of its population in the event of an epidemic.
In a statement, Biota said that while the financial terms of the contract have not been revealed, it represents a potential royalty to the Melbourne company of up to $18 million.
Last year, Biota dropped long-standing legal action against GSK for failing to market Relenza properly. The company said it had lost up to $400 million in potential royalties but eventually settled the case for $20 million.
The company is now in Phase III trials of a long-acting neuraminidase inhibitor, developed with partner Daiichi Sankyo, for human and bird flu.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
